Delayed to Diagnosed: Systemic Mastocytosis in Clinical Practice
A disease awareness webinar hosted by Blueprint Medicines
Presented by Dr. Miguel Piris Villaspesa and Dr. Cristina Papayannidis
Systemic mastocytosis (SM) is a genetic disorder caused by abnormal proliferation of mast cells, with an estimated prevalence of ~1 in 10,000.1,2
Like many rare diseases, SM often hides in the shadows due to its impact on multiple organs beyond the skin.2
Learning objectives:
- Identify the common and often overlooked “red flag” symptoms of SM to help facilitate earlier diagnosis
- Acquire knowledge of essential diagnostic tests for SM and navigate the differential diagnosis process effectively
- Understand the challenges faced by patients living with SM and their impact on quality of life
- Analyse detailed case studies to illustrate the diagnostic journey and the value of timely diagnosis
- Engage with leading experts to gain real-time insights
Could your patient be one of the undiagnosed? Register now and take the first step towards recognising SM sooner and help shorten the diagnosis journey.
Google
Apple
OutlookPresenters
Dr. Miguel Piris Villaespesa
Dr. Miguel Piris Villaespesa is a Consultant Haematologist and co-ordinates the Multidisciplinary Mastocytosis Unit at the Ramón y Cajal University Hospital in Madrid, Spain. Dr. Piris Villaespesa’s research interests centre on myeloproliferative neoplasms and chronic lymphocytic leukaemia, with a commitment to integrated haematological diagnosis and the management of patients with mastocytosis. Having built on his experience in these areas, he is the author of more than 25 papers in international journals and has participated in numerous conferences in the field of systemic mastocytosis. He has been involved in approximately 50 clinical trials and led two large studies on systemic mastocytosis. Additionally, he is a member of the board of the Spanish Group of Advanced Systemic Mastocytosis (GEMAST).
Dr. Cristina Papayannidis
Dr. Cristina Papayannidis is an Adjunct Professor of Haematology at IRCCS Azienda Ospedaliero-Universitaria di Bologna in Bologna, Italy. Dr. Papayannidis has conducted numerous clinical trials in the field of haematology and is a member of several professional organisations, including the European Haematology Association (EHA) and the European Society for Medical Oncology (ESMO). Her research primarily focuses on unravelling the complexities of acute leukaemia and systemic mastocytosis, advancing the understanding and treatment of these challenging conditions.
Register your attendance
Blueprint Medicines and associated logos are trademarks of Blueprint Medicines Corporation.
®2024 Blueprint Medicines (Netherlands) B.V. INTBP-DAXSM-24.011v1.0 08/24
